Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Yep, heres yur IR Guyz....geeeeez http://www.sec.gov/litigation/litreleases/2010/lr21449.htm
Heard major push coming here..LMFAOO Tampa Boy still has shares?..wtf
AFTC radar for the week
AFTC radar this week
EMGE nice
Yep, head scratcher...lol I got this from msnbc..They are ALVAC, from Sanofi Pasteur, the vaccine division of French drugmaker Sanofi-Aventis; and AIDSVAX, originally developed by VaxGen Inc. and now held by Global Solutions for Infectious Diseases, a nonprofit founded by some former VaxGen employees.
VXGN 1.10's in pmkt WOWOWOWOWOW
VXGN 1.10'S going geeez
Already 1.00 pmkt...hmmmm VXGN
VXGN >>> HUGE NEWS ABOUT VACCINE ON MSNBC >> RADAR
VXGN VACCINE NEWS GONNA GO NUTZ HERE
XOMA gappa
VXGN.OB THIS IS BIG >>> For first time, a vaccine helps prevent HIV
This is on msnbc.com !!!
Risk of infection cut by 31 percent in Thai trial of 16,000 volunteers
msnbc.com
updated 1:42 a.m. PT, Thurs., Sept . 24, 2009
BANGKOK - For the first time, an experimental vaccine has prevented infection with the AIDS virus, a watershed event in the deadly epidemic and a surprising result. Recent failures led many scientists to think such a vaccine might never be possible.
The vaccine cut the risk of becoming infected with HIV by more than 31 percent in the world's largest AIDS vaccine trial of more than 16,000 volunteers in Thailand, researchers announced Thursday in Bangkok.
Even though the benefit is modest, "it's the first evidence that we could have a safe and effective preventive vaccine," Col. Jerome Kim said in a telephone interview. He helped lead the study for the U.S. Army, which sponsored it with the National Institute of Allergy and Infectious Diseases.
The institute's director, Dr. Anthony Fauci, warned that this is "not the end of the road," but said he was surprised and very pleased by the outcome.
"It gives me cautious optimism about the possibility of improving this result" and developing a more effective AIDS vaccine, Fauci said in a telephone interview. "This is something that we can do."
‘Historic milestone’
Even a marginally helpful vaccine could have a big impact. Every day, 7,500 people worldwide are newly infected with HIV; 2 million died of AIDS in 2007, the U.N. agency UNAIDS estimates.
"Today marks an historic milestone," said Mitchell Warren, executive director of the AIDS Vaccine Advocacy Coalition, an international group that has worked toward developing a vaccine.
"It will take time and resources to fully analyze and understand the data, but there is little doubt that this finding will energize and redirect the AIDS vaccine field," he said in a statement.
The Thailand Ministry of Public Health conducted the study, which used strains of HIV common in Thailand. Whether such a vaccine would work against other strains in the U.S., Africa or elsewhere in the world is unknown, scientists stressed.
The study actually tested a two-vaccine combo in a "prime-boost" approach, where the first one primes the immune system to attack HIV and the second one strengthens the response.
They are ALVAC, from Sanofi Pasteur, the vaccine division of French drugmaker Sanofi-Aventis; and AIDSVAX, originally developed by VaxGen Inc. and now held by Global Solutions for Infectious Diseases, a nonprofit founded by some former VaxGen employees.
ALVAC uses canarypox, a bird virus altered so it can't cause human disease, to ferry synthetic versions of three HIV genes into the body. AIDSVAX contains a genetically engineered version of a protein on HIV's surface. The vaccines are not made from whole virus — dead or alive — and cannot cause HIV.
Neither vaccine in the study prevented HIV infection when tested individually in earlier trials, and dozens of scientists had called the new one futile when it began in 2003.
"I really didn't have high hopes at all that we would see a positive result," Fauci confessed.
Skeptics proved wrong
The results proved the skeptics wrong.
"The combination is stronger than each of the individual members," said the Army's Kim.
The study tested the combo in HIV-negative Thai men and women ages 18 to 30 at average risk of becoming infected. Half received four "priming" doses of ALVAC and two "boost" doses of AIDSVAX over six months. The others received dummy shots. No one knew who got what until the study ended.
All were given condoms, counseling and treatment for any sexually transmitted infections, and were tested every six months for HIV. Any who became infected were given free treatment with antiviral medicines.
Participants were followed for three years after vaccination ended.
Results: New infections occurred in 51 of the 8,197 given vaccine and in 74 of the 8,198 who received dummy shots. That worked out to a 31 percent lower risk of infection for the vaccine group.
The vaccine had no effect on levels of HIV in the blood of those who did become infected. That had been another goal of the study — seeing whether the vaccine could limit damage to the immune system and help keep infected people from developing full-blown AIDS.
That result is "one of the most important and intriguing findings of this trial," Fauci said. It suggests that the signs scientists have been using to gauge whether a vaccine was actually giving protection may not be valid.
"It is conceivable that we haven't even identified yet" what really shows immunity, which is both "important and humbling" after decades of vaccine research, Fauci said.
Details of the $105 million study will be given at a vaccine conference in Paris in October.
Third big trial
This is the third big vaccine trial since 1983, when HIV was identified as the cause of AIDS. In 2007, Merck & Co. stopped a study of its experimental vaccine after seeing it did not prevent HIV infection. Later analysis suggested the vaccine might even raise the risk of infection in certain men. The vaccine itself did not cause infection.
In 2003, AIDSVAX flunked two large trials — the first late-stage tests of any AIDS vaccine at the time.
It is unclear whether vaccine makers will seek to license the two-vaccine combo in Thailand. Before the trial began, the U.S. Food and Drug Administration said other studies would be needed before the vaccine could be considered for U.S. licensing.
Also unclear is whether Thai volunteers who received dummy shots will now be offered the vaccine. Researchers had said they would do so if the vaccine showed clear benefit — defined as reducing the risk of infection by at least 50 percent.
Those issues, plus how to proceed with future studies, will be discussed among the governments, study sponsors and companies involved in the trial, Kim said. Scientists want to know how long will protection last, whether booster shots will be needed, and whether the vaccine helps prevent infection in gay men and injection drug users, since it was tested mostly in heterosexuals in the Thai trial.
The study was done in Thailand because U.S. Army scientists did pivotal research in that country when the AIDS epidemic emerged there, isolating virus strains and providing genetic information on them to vaccine makers. The Thai government also strongly supported the idea of doing the study.
XOMA HUGE NEWS---GOOD WEAK HAND SHAKE---GAPPER AM IMO
XOMA HUGE NEWS---GOOD WEAK HAND SHAKE---GAPPER AM IMO
XOMA eod add...should be strong am imo
EOD shake...setting up 4 tomorrow
XOMA shake done now she BLOWSSS
Tomorrow GAP GAP GAP BOOM >>>>>>>>>
XOMA A MONSTER TOMORROW IMHO
XOMA A MONSTER TOMORROW IMHO
XOMA HUGE VOL POURING IN NOW
XOMA shake and thinnnnnnnnn
XOMA here we go
XOMA HUGE NEWZZZ GOING HERE >>>>>>
in XOMA on h1n1 newzzz
RBRM HUGE NEWS >>>>> RADAR >>>>> ReBuilder Medical Technologies, Inc. Announces Medicare Billing Ability for its ReBuilder Product
50 minutes ago - Pr Newswire
Related Companies
Symbol Last %Chg
RBRM 0.02 17.65%
As of 1:23 PM ET 9/23/09
ReBuilder Medical Technologies, Inc. (Pink Sheets: RBRM) a provider of novel electronic treatments for the pain resulting from peripheral neuropathy and arthritis today announced that it has received full accreditation as a Medicare provider for Medicare claims for the ReBuilder.
(Logo: http://www.newscom.com/cgi-bin/prnh/20061128/REBUILDERLOGO)
Physicians all over the U.S. are now using the ReBuilder as their first choice for the treatment of leg pain. Many of them are not registered with Medicare so they cannot provide the ReBuilder to their patients with Medicare.
"Now that we can bill Medicare directly," said David Phillips, Ph.D. CEO, "customers who want a ReBuilder can now use their Medicare benefits. This means that with their secondary insurance, our customers will have little or no money to pay out of pocket. This may result in an immediate 4-fold increase in sales."
Additionally, Dr. Phillips reports: "We are now accepting Medicare business and we began to submit claims last Friday, Sept 18, 2009."
Finally, Dr. Phillips told reporters today: "We have waited a long time to get into this exciting phase of our business. Already we are flooded with new orders."
Inquiries can be made at www.rebuildermedical.com.
Safe Harbor: This letter contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbors created thereby. Investors are cautioned that all forward-looking statements involve risks and uncertainty, including without limitation, the ability of the Company to successfully implement its turnaround strategy, changes in costs of raw materials, labor, and employee benefits, as well as general market conditions, competition and pricing. Although the Company believes that the assumptions underlying the forward-looking statements contained herein are reasonable, any of the assumptions could be inaccurate, and therefore, there can be no assurance that the forward-looking statements included in this letter will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as representation by the Company or any other person that the objectives and plans of the Company will be achieved. In assessing forward-looking statements included herein, readers are urged to carefully read those statements. When used in the Annual Report on Form 10-K, the words "estimate," "anticipate," "expect," "believe," and similar expressions are intended to be forward-looking statements.
SOURCE ReBuilder Medical Technologies, Inc.
http://www.rebuildermedical.com
RBRM HUGE NEWS >>>> RADAR
ReBuilder Medical Technologies, Inc. Announces Medicare Billing Ability for its ReBuilder Product
45 minutes ago - Pr Newswire
Related Companies
Symbol Last %Chg
RBRM 0.02 17.65%
As of 1:23 PM ET 9/23/09
ReBuilder Medical Technologies, Inc. (Pink Sheets: RBRM) a provider of novel electronic treatments for the pain resulting from peripheral neuropathy and arthritis today announced that it has received full accreditation as a Medicare provider for Medicare claims for the ReBuilder.
(Logo: http://www.newscom.com/cgi-bin/prnh/20061128/REBUILDERLOGO)
Physicians all over the U.S. are now using the ReBuilder as their first choice for the treatment of leg pain. Many of them are not registered with Medicare so they cannot provide the ReBuilder to their patients with Medicare.
"Now that we can bill Medicare directly," said David Phillips, Ph.D. CEO, "customers who want a ReBuilder can now use their Medicare benefits. This means that with their secondary insurance, our customers will have little or no money to pay out of pocket. This may result in an immediate 4-fold increase in sales."
Additionally, Dr. Phillips reports: "We are now accepting Medicare business and we began to submit claims last Friday, Sept 18, 2009."
Finally, Dr. Phillips told reporters today: "We have waited a long time to get into this exciting phase of our business. Already we are flooded with new orders."
Inquiries can be made at www.rebuildermedical.com.
Safe Harbor: This letter contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbors created thereby. Investors are cautioned that all forward-looking statements involve risks and uncertainty, including without limitation, the ability of the Company to successfully implement its turnaround strategy, changes in costs of raw materials, labor, and employee benefits, as well as general market conditions, competition and pricing. Although the Company believes that the assumptions underlying the forward-looking statements contained herein are reasonable, any of the assumptions could be inaccurate, and therefore, there can be no assurance that the forward-looking statements included in this letter will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as representation by the Company or any other person that the objectives and plans of the Company will be achieved. In assessing forward-looking statements included herein, readers are urged to carefully read those statements. When used in the Annual Report on Form 10-K, the words "estimate," "anticipate," "expect," "believe," and similar expressions are intended to be forward-looking statements.
SOURCE ReBuilder Medical Technologies, Inc.
http://www.rebuildermedical.com
TVCE good call
ONCP .0019'S EVAPORATING
ONCP +171%
ONCP +171%
ONCP .0019'S LEAVING
ONCP +157%
YUP ONCP + 157%
ONCP SWEET
nice turn---NOW GOOOOOOOOOOOOOO
ONCP +170%
ONCP +170%
Nice momo 1st half hour 10 day shattered